ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 570,20
-0,77%
Dow Jones
38 834,86
0,15%
DAX
18 067,91
-0,31%
Brent Oil
84,515
-0,21%
Bitcoin
65 147,22
0,28%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Aurinia Pharmaceuticals Inc (AUPH)

  7. Aurinia Pharmaceuticals Inc (AUPH) Actualités

AUPH Aurinia Pharmaceuticals Inc

5,44
-0,10 (-1,81%)
19 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Aurinia Pharmaceuticals Inc AUPH NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,10 -1,81% 5,44 01:55:19
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
5,49 5,41 5,63 5,42 5,54
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
14/6/202423:25EDGAR2Form 8-K - Current report
14/6/202418:16BWAurinia Announces 2024 Annual General Meeting Results
05/6/202412:00BWAurinia Presents Safety and Efficacy Profile of LUPKYNIS®..
04/6/202423:30BWAurinia Addresses Dubious Proposals Put Forth by Lucien..
04/6/202423:25EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
04/6/202400:30BWAurinia Provides Update on Proxy Statement
30/5/202412:00BWAurinia Will Attend 2024 Jefferies Global Healthcare..
22/5/202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202422:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/5/202412:00BWAnalysis Showing LUPKYNIS® is a Cost-Effective Treatment for..
09/5/202412:00BWAurinia Presents Data Reinforcing LUPKYNIS® Safety and..
07/5/202412:00BWAurinia Will Attend 2024 RBC Capital Markets Global..
02/5/202412:00BWAurinia Pharmaceuticals Reports First Quarter 2024 Financial..
01/5/202412:00BWAurinia Underscores Enduring Commitment to People Living..
30/4/202412:00BWThe U.S. Food & Drug Administration (FDA) Approves Updated..
16/4/202416:48BWUPDATE: New Aurinia Presentation Details at the 2024 Bloom..
15/4/202412:00BWAurinia Pharmaceuticals to Release First Quarter Financial..
09/4/202412:00BWAurinia Will Attend 2024 Bloom Burton & Co. Healthcare..
07/3/202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:10EDGAR2Form 8-K - Current report
29/2/202414:30BWAurinia Receives Exemptive Relief from Canadian Securities..
27/2/202414:30BWAurinia to Participate in Upcoming Investor Healthcare..
22/2/202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202422:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202422:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202422:19EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
15/2/202412:16EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
15/2/202412:06EDGAR2Form 8-K - Current report
15/2/202412:00BWAurinia Discloses 2023 Year-End Financial and Operational..
14/2/202421:27EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/2/202414:30BWAurinia Pharmaceuticals to Release 2023 Fourth Quarter and..
05/1/202412:02EDGAR2Form 8-K - Current report
05/1/202412:00BWAurinia Provides Preliminary Unaudited Fourth Quarter and..
20/12/202312:00BWAurinia Submits IND Application to US Food & Drug..
13/11/202312:00BWAurinia Pharmaceuticals Announces Collaboration Partner..
07/11/202316:30BWAurinia Presents Breadth of Data from AURORA Clinical..
02/11/202323:00BWAurinia Presents Breadth of Data at ASN 2023 Demonstrating..
02/11/202311:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202311:01EDGAR2Form 8-K - Current report
02/11/202311:00BWAurinia Pharmaceuticals Reports Third Quarter and Nine..
26/10/202321:00BWAurinia Response in Support of 2023 Updated EULAR..
19/10/202316:31BWCORRECTING and REPLACING Aurinia Pharmaceuticals to Release..

Dernières Valeurs Consultées

NASDAQ
AUPH
Aurinia Pharmaceuticals
EU
FR001400OWS6
Pays of the Loire Region...
BIT
P1VUC1
NLBNPIT1VUC1 20991231 95...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés